Short Interest in Aprea Therapeutics, Inc. (NASDAQ:APRE) Rises By 271.1%

Posted by Eileen French on Feb 12th, 2025

Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) saw a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 44,900 shares, a growth of 271.1% from the January 15th total of 12,100 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average daily volume of 28,300 shares, the short-interest ratio is presently 1.6 days.

Aprea Therapeutics Stock Performance

Shares of NASDAQ:APRE traded up $0.12 during trading hours on Wednesday, reaching $3.43. The stock had a trading volume of 8,490 shares, compared to its average volume of 38,521. Aprea Therapeutics has a 1 year low of $2.15 and a 1 year high of $8.85. The stock has a market capitalization of $18.62 million, a price-to-earnings ratio of -1.22 and a beta of 0.76. The firm’s 50 day moving average is $3.61 and its 200-day moving average is $3.44.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Aprea Therapeutics in a research note on Wednesday, January 15th.

Get Our Latest Report on Aprea Therapeutics

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP bought a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 34.19% of the stock is currently owned by institutional investors and hedge funds.

About Aprea Therapeutics

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.